Ocuphire Pharma
summary to have a clinically meaningful impact on slowing or preventing progression to reduce likelihood of vision loss in diabetic patients owing | Ocuphire Pharma
Company
Deck Type
Deck date
November 2023
Slide
30 of 42
Related slides by other companies
Equillium
Investor Presentation
August 2023
driving development towards option decision two data deliverables expected in a | Equillium
Chimerix
Investor Presentation
August 2023
deal term summary emergent is an experienced company collaborating with government agencies to protect public health terms summary million received at closing in up to an additional million in potential procurement milestones royalty on future gross profit with volumes above million courses of therapy royalty of all international gross profit up to an additional million in development milestones a oral suspension tablets tembe me | Chimerix
Inovalon
Results
May 2018
expand reach accelerate impact patients provider sites | Inovalon
RayzeBio
IPO
September 2023
isotope clinically effective but patients invariably progress | RayzeBio
Other recent decks by Ocuphire Pharma
See all presentations (10 decks)
Investor Presentation
August 2023
Investor Presentation
May 2023
Results
January 2023
Results
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights